Publications by authors named "M C P Kuppen"
Background: Manual data collection is still the gold standard for disease-specific patient registries. However, CAPRI-3 uses text mining (an artificial intelligence (AI) technology) for patient identification and data collection. The aim of this study is to demonstrate the reliability and efficiency of this AI-driven approach.
View Article and Find Full Text PDFArticle Synopsis
- - This study analyzed real-world data from CRPC patients to assess how common visceral metastases (VMs) are and how they affect patient survival, using data from the CAPRI registry over several years.
- - Out of 3602 patients, 12.7% were diagnosed with VMs, with varying survival rates based on the type of metastases: median survival was 8.6 months for liver, 18.3 months for lung, and 10.9 months for both types.
- - Despite a rising trend in screening for VMs as treatment progresses, a significant number of patients (80% at diagnosis to 40% by the sixth treatment line) were still not screened, highlighting the importance of
Background: Real-world disease models spanning multiple treatment lines can provide insight into the (cost) effectiveness of treatment sequences in clinical practice.
Objective: Our objective was to explore whether a disease model based solely on real-world data (RWD) could be used to estimate the effectiveness of treatments for patients with castration-resistant prostate cancer (CRPC) that could then be suitably used in a cost-effectiveness analysis.
Methods: We developed a patient-level simulation model using patient-level data from the Dutch CAPRI registry as input parameters.
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.
Clin Genitourin Cancer
February 2022
Background: Patients with metastatic castration resistant prostate cancer (mCRPC) are at risk of symptomatic skeletal events (SSE). Bone health agents (BHA, ie bisphosphonates and denosumab) and new life-prolonging drugs (LPDs) can delay SSEs. The aim of this study is to investigate the use of BHAs in relation to SSEs in treated real-world mCRPC population.
View Article and Find Full Text PDFIntensive end-of-life care (i.e., the overuse of treatments and hospital resources in the last months of life), is undesirable since it has a minimal clinical benefit with a substantial financial burden.
View Article and Find Full Text PDF